<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-10-31">31 October 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Gabriele</forename><surname>Nagel</surname></persName>
							<email>gabriele.nagel@uni-ulm.de</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Epidemiology and Medical Biometry</orgName>
								<orgName type="institution">Ulm University</orgName>
								<address>
									<addrLine>Helmholtzstr. 22</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">D</forename><surname>Weber</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Fromm</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Epidemiology and Medical Biometry</orgName>
								<orgName type="institution">Ulm University</orgName>
								<address>
									<addrLine>Helmholtzstr. 22</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">S</forename><surname>Erhardt</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Epidemiology and Medical Biometry</orgName>
								<orgName type="institution">Ulm University</orgName>
								<address>
									<addrLine>Helmholtzstr. 22</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">M</forename><surname>Lübbert</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University Hospital Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">W</forename><surname>Fiedler</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Internal Medicine II</orgName>
								<orgName type="institution">University Hospital Hamburg-Eppendorf</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Kindler</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Medical Center Mainz</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Internal Medicine III, Hospital Braunschweig</orgName>
								<address>
									<settlement>Braunschweig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Brossart</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital of Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Kündgen</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Hematology, Oncology and Clinical Immunology</orgName>
								<orgName type="institution">University Hospital of Düsseldorf</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Salih</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Internal Medicine II</orgName>
								<orgName type="institution">University Hospital of Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Westermann</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité -Campus Virchow Clinic</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Wulf</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital of Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">B</forename><surname>Hertenstein</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">Hospital Bremen-Mitte</orgName>
								<address>
									<settlement>Bremen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">M</forename><surname>Wattad</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Hospital Essen-Werden</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">K</forename><surname>Götze</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Klinikum rechts der Isar</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Kraemer</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Oncology and Hematology</orgName>
								<orgName type="institution">Hospital Oldenburg</orgName>
								<address>
									<settlement>Oldenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Heinicke</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital of Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">M</forename><surname>Girschikofsky</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Hospital Elisabethinen Linz</orgName>
								<address>
									<settlement>Linz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Derigs</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">Hospital Frankfurt-Hoechst</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Horst</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Internal Medicine II</orgName>
								<orgName type="institution">University Hospital of Schleswig-Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Rudolph</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Heuser</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">and Stem Cell Transplantation</orgName>
								<address>
									<settlement>Hemostasis, Hannover</settlement>
									<region>Oncology</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Göhring</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Institute of Human Genetics</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Teleanu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Thol</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">and Stem Cell Transplantation</orgName>
								<address>
									<settlement>Hemostasis, Hannover</settlement>
									<region>Oncology</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Gaidzik</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Paschka</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Döhner</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">A</forename><surname>Ganser</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">and Stem Cell Transplantation</orgName>
								<address>
									<settlement>Hemostasis, Hannover</settlement>
									<region>Oncology</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hartmut</forename><surname>Döhner</surname></persName>
							<email>hartmut.doehner@uniklinik-ulm.de</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<addrLine>Albert-Einstein-Allee 23</addrLine>
									<postCode>89081</postCode>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="institution" key="instit1">NCT Trial Center</orgName>
								<orgName type="institution" key="instit2">National Center for Tumor Diseases</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><surname>German-Austrian</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="laboratory">AML Study Group (AMLSG)</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-10-31">31 October 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">40F7313A8B30EA6E4DCE03E68D5A59F7</idno>
					<idno type="DOI">10.1007/s00277-017-3150-3</idno>
					<note type="submission">Received: 17 August 2017 / Accepted: 16 September 2017 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:45+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Epidemiology</term>
					<term>Genetics</term>
					<term>Older age</term>
					<term>AML</term>
					<term>Registry</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Acute myeloid leukemia (AML) is the most frequent acute leukemia in adults with an incidence of 3 to 4 per 100,000 persons per year <ref type="bibr">[1,</ref><ref type="bibr" target="#b13">2]</ref>.</s><s>The median age at diagnosis ranges from 66 to 71 years [1, <ref type="bibr" target="#b14">3,</ref><ref type="bibr" target="#b15">4]</ref>.</s><s>Of note, over the last years the incidence has remained stable in younger patients but significantly increased in patients aged over 75 years <ref type="bibr" target="#b14">[3,</ref><ref type="bibr" target="#b16">5]</ref>.</s><s>AML is a genetically very heterogeneous disorder characterized by the accumulation of somatically acquired genetic changes in hematopoietic progenitor cells that alter normal mechanisms of self-renewal, proliferation, and differentiation <ref type="bibr" target="#b17">[6]</ref>.</s><s>Treatment approaches are influenced by various factors, including patient features such as age, comorbidities, body mass index (BMI), and performance status as well as disease characteristics whereby the genetic profile of the disease is the most important prognostic factor <ref type="bibr" target="#b14">[3,</ref><ref type="bibr" target="#b18">[7]</ref><ref type="bibr" target="#b19">[8]</ref><ref type="bibr" target="#b20">[9]</ref><ref type="bibr" target="#b21">[10]</ref><ref type="bibr" target="#b22">[11]</ref>.</s></p><p><s>Scientific and technical advances accelerate the development and application of molecular genetic testing in subjects with leukemia.</s><s>Mutations in the genes such as nucleophosmin-1 (NPM1), FMS-related tyrosine kinase 3 (FLT3), and CCAAT/ enhancer-binding protein alpha (CEBPA) in cytogenetically normal AML influence the prognosis of AML patients <ref type="bibr" target="#b23">[12]</ref> and have entered clinical routine <ref type="bibr" target="#b22">[11,</ref><ref type="bibr" target="#b24">13]</ref>.</s><s>Activating FLT3 mutations including internal tandem duplication (ITD) as well as tyrosine kinase domain (TKD) mutations and point mutations in exone 12 of NPM1 are reported as frequent mutations in AML in an average young trial population with reported incidences of 33 and 28%, respectively <ref type="bibr" target="#b19">[8]</ref>, whereas mutations in CEBPA are less frequent <ref type="bibr" target="#b23">[12]</ref>.</s><s>In 2010, the European LeukemiaNet (ELN) proposed a standardized reporting system integrating cytogenetic and molecular genetic data which recently has been updated <ref type="bibr" target="#b24">[13]</ref>.</s><s>In addition, the efficacy and availability of FLT3 inhibitors mark the starting point beyond acute promyelocytic leukemia of genotype-directed therapy in AML.</s><s>Recently, the multi-kinase inhibitor midostaurin has shown efficacy in a randomized phase III trial of patients with activating FLT3 mutations <ref type="bibr" target="#b25">[14]</ref>.</s></p><p><s>The introduction of personalized medicine will pose new challenges with respect to transition into clinical routine and in the evaluation of new treatment approaches in small genetically defined subgroups <ref type="bibr" target="#b19">[8,</ref><ref type="bibr" target="#b26">15]</ref>.</s><s>Most of our knowledge on leukemia has been derived from center-and cooperative group-based clinical data rather than population-based registries <ref type="bibr" target="#b15">[4,</ref><ref type="bibr" target="#b27">16,</ref><ref type="bibr" target="#b28">17]</ref>.</s><s>Due to this increasing heterogeneity, registries are a valuable data source to appraise the presenting clinical characteristics and treatment decision in AML patients <ref type="bibr" target="#b15">[4]</ref>.</s><s>There is evidence from population-based registries that the survival expectations of patients with AML have improved over the past decades <ref type="bibr" target="#b28">[17,</ref><ref type="bibr" target="#b29">18]</ref>, whereby in older AML patients only little or no progress has been made <ref type="bibr" target="#b16">[5,</ref><ref type="bibr" target="#b30">19,</ref><ref type="bibr" target="#b31">20]</ref>.</s><s>This difference probably reflects the difference in disease profile and frequency as well as severity of comorbidities in older compared to younger patients <ref type="bibr" target="#b14">[3,</ref><ref type="bibr" target="#b20">9,</ref><ref type="bibr" target="#b24">13]</ref>.</s><s>However, our understanding of genetic heterogeneity according to patients' demographic, clinical, and treatment characteristics is still incomplete <ref type="bibr" target="#b28">[17,</ref><ref type="bibr" target="#b29">18]</ref>.</s></p><p><s>The objectives of our study were to investigate epidemiological, genetic, and clinical characteristics of patients participating in the German-Austrian AML Study Group registry study (AMLSG BiO; ClinicalTrials.gov</s><s>Identifier: NCT01252485) from 2012 to 2014, to compare them with selected epidemiological cancer registry data and to analyze distributions of genetic, clinical, and treatment characteristics according to age.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>The AMLSG BiO registry study was initiated in 2010, and activation of most sites was completed in 2011.</s><s>We aimed to analyze epidemiological, genetic, and clinical features between 2012 and 2014, representing a period of 2 years with full recruitment.</s><s>We intended to register all patients aged 18 years or older with newly diagnosed AML at all centers of the German-Austrian AML Study Group (AMLSG) within the AMLSG BiO registry study.</s><s>Via a web-based system, participating AMLSG centers registered patients with newly diagnosed AML based on local bone marrow and peripheral blood assessment after written informed consent.</s><s>In all patients, bone marrow and peripheral blood samples were sent overnight by courier service to the AMLSG reference laboratories for cytogenetic and molecular genetic analyses (University of Ulm, Hannover Medical School).</s><s>The study was approved by the ethical review boards of all participating centers.</s></p><p><s>For the current analysis, 3521 AML cases diagnosed between January 1, 2012, and December 31, 2014, were identified in the AMLSG BiO registry study database.</s><s>Data were collected on sex, age, date of diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status <ref type="bibr" target="#b32">[21]</ref>, and comorbidities according to the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) <ref type="bibr" target="#b33">[22]</ref>.</s><s>AML cases were classified according to the 2008 World Health Organization (WHO) proposal <ref type="bibr" target="#b34">[23]</ref> and risk-stratified according to the 2010 ELN classification <ref type="bibr" target="#b22">[11]</ref>.</s><s>In 3213 (91%) patients, information on treatment strategy was available including intensive chemotherapy, non-intensive treatment (azacitidine, decitabine, low-dose cytarabine), and best supportive care (BSC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytogenetics and molecular genetics</head><p><s>Chromosome banding analysis (within 14 days) and molecular screening (within 48 h) were performed in the two AMLSG central laboratories in Hannover and Ulm.</s><s>Karyotypes were described according to the International System for Human Cytogenetic Nomenclature <ref type="bibr" target="#b35">[24]</ref>.</s><s>Leukemia samples were analyzed for mutations in FLT3 (ITDs, and tyrosine kinase domain [TKD] mutations at codons D835/I836), NPM1, and CEBPA (both monoallelic and biallelic) as previously described <ref type="bibr" target="#b23">[12,</ref><ref type="bibr" target="#b36">25,</ref><ref type="bibr" target="#b37">26]</ref>.</s></p><p><s>The molecular profile of the disease in conjunction with a recommendation of potential trial participation was documented in a web-based system, and results were communicated immediately via facsimile to the participating centers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>Age-standardized incidence rates (ASR) of AML for Germany (N = 3251) were calculated using German population data in the years 2012-2014 <ref type="bibr" target="#b38">[27]</ref>.</s><s>Based on the geographic distribution of the contributing centers (Supplemental Fig. <ref type="figure" target="#fig_0">1</ref>) with no or only few centers in Mecklenburg-Pommerania, Brandenburg, Thuringia, Saxony, and Bavaria, the data from these regions were excluded from the denominator of the population data.</s></p><p><s>For the AML diagnosis (ICD-9: 205.0 or ICD-10 C92.0), the incidence rates by sex and 5-year age classes were provided by the following cancer registries: Saarland (2006-2010), Bavaria (2010-2012), and North Rhine-Westphalia <ref type="bibr">(2010)</ref><ref type="bibr">(2011)</ref><ref type="bibr">(2012)</ref><ref type="bibr">(2013)</ref>.</s><s>Based on the data, mean annual incidence rates were calculated.</s><s>In addition, data on AML from the Surveillance, Epidemiology, and End Results (SEER) program in the USA was used <ref type="bibr" target="#b40">[28]</ref>.</s></p><p><s>Multinomial logistic regression was calculated to estimate odds ratios (OR) and the 95% confidence intervals (95% CI) for treatment strategy (reference: intensive chemotherapy).</s><s>The covariates age class, sex, ECOG performance status, ELN risk category, HCT comorbidity index, and BMI (&lt; 20, 20-24, &gt; 25 kg/m 2 ) were entered simultaneously as independent variables into the final model to determine their effects on treatment decision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Between 2012 and 2014, 3521 patients with newly diagnosed AML (45% women) were registered.</s><s>The baseline characteristics of the AMLSG BiO study population are described in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Overall, the median age was 65 years (Q1, Q3; 54, 74, range 18-94); men were slightly older than women (median age 66 vs. 64 years).</s><s>Independent of gender, most AML cases were observed in the age group 70 years and older (N = 1396, 39.7%).</s><s>The age-specific incidence rates for AML in Germany are shown in Fig. <ref type="figure" target="#fig_0">1a</ref> (for men), b (for women).</s><s>The comparison of the age-specific AML incidence rates with data from German epidemiological cancer registries in Bavaria, North Rhine-Westphalia, and Saarland as well as the US SEER cancer database revealed good coverage of AML patients in the AMLSG BiO registry in younger and middle age classes, while older patients were less frequently registered.</s><s>In both men and women, the incidence rates increased with age.</s></p><p><s>In the AMLSG BiO registry, most registered cases were defined as de novo AML (82.1%), followed by secondary AML evolving after a myelodysplastic syndrome (13.6%) and therapy-related AML (4.3%).</s><s>Mutated NPM1 was present in 914 patients (26%), followed by FLT3-ITD in 666 (18.9%) and FLT3-TKD mutations in 219 (6.2%) cases.</s><s>In women, FLT3-ITD and mutated NPM1 were more prevalent than in men (both p values &lt; 0.0001).</s><s>According to the 2010 ELN classification, patients were diagnosed with favorable (N = 534, 20.2%), intermediate risk-1 (N = 819, 31%), intermediate risk-2 (N = 735, 27.8%), and adverse risk (N = 558, 21.1%).</s><s>Categorization of cases according to the 2008 WHO classification revealed AML with recurrent genetic abnormalities as the largest subgroup (41.2%) including the two provisional entities AML with mutated NPM1 (25.3%) and AML with mutated CEBPA (4.2%), followed by AML not otherwise specified (30.5%),</s><s>AML with MDS-related changes (24.5%), and therapy-related AML (3.8%) (Fig. <ref type="figure">2</ref>).</s></p><p><s>Absolute and relative prevalence according to age groups as well as according to the 2010 ELN risk groups, HCT  <ref type="figure">3a</ref>).</s><s>Thus, the relative prevalence of favorable-risk AML decreased whereas the absolute prevalence remained stable with increasing age.</s><s>In contrast, the absolute and relative numbers of patients in the adverse risk group consistently increased with increasing age.</s><s>Overall, most patients (39%) presented with no comorbidity burden (HCT-CI 0) with nearly stable absolute numbers across the different age groups, whereas the absolute and relative prevalence of patients with limited (HCT-CI 1-2) and extensive (HCT-CI ≥ 3) HCT comorbidity index increased with increasing age (Fig. <ref type="figure">3b</ref>).</s><s>A similar relationship was present for the ECOG performance status with a nearly stable absolute prevalence but decreasing relative frequency of fully active (ECOG 0) patients, whereas patients with slightly to moderately diminished performance status (ECOG 1/2) represented the largest group in older age groups (age 60-69 years, age ≥ 70 years) (Fig. <ref type="figure">3c</ref>).</s><s>Based on the performance status (ECOG ≤ 2), most of our patients were eligible for intensive chemotherapy even in the age group ≥ 70 years.</s></p><p><s>We were also interested in the distribution of patients with activating FLT3-ITD and FLT3-TKD mutations due to potentially available targeted therapy <ref type="bibr" target="#b25">[14]</ref>.</s><s>Although the relative numbers decreased significantly with increasing age, the absolute number of patients with activating FLT3 mutations increased with age (&lt; 45 years, n = 135; 45-59 years, n = 245; 60-69 years, n = 203; ≥ 70 years, n = 271; Fig. <ref type="figure">3d</ref>).</s><s>Based on reported very good response rates achieved in NPM1-mutated AML with intensive induction therapy <ref type="bibr" target="#b20">[9]</ref><ref type="bibr" target="#b21">[10]</ref><ref type="bibr" target="#b22">[11]</ref><ref type="bibr" target="#b23">[12]</ref>, we performed an additional analysis according to NPM1 mutational status and age.</s><s>The percentages (absolute numbers) of patients with NPM1 mutations according to the four age groups in ascending order were 24% (n = 100), 34% (n = 281), 27% (n = 238), and 21% (n = 295) indicating that even in age group ≥ 70 years a substantial number of patients could potentially benefit from intensive induction chemotherapy (suppl.</s><s>Figure <ref type="figure">3</ref>).</s></p><p><s>Most of the patients with information on treatment (N = 3213) received intensive chemotherapy (71.1%,</s><s>Table <ref type="table" target="#tab_0">1</ref>).</s><s>However, starting with the age of 65 years, a substantial and increasing proportion of patients received either non-intensive therapy or best supportive care (BSC) (Fig. <ref type="figure">4</ref>) reaching a proportion of more than 50% in patients &gt; 75 years.</s></p><p><s>In multivariate models (Table <ref type="table" target="#tab_1">2</ref>), age &gt; 70 years was the strongest predictor to receive non-intensive treatment (OR, 9.91; 95% CI, 7.08-13.86;</s><s>reference, intensive chemotherapy) or BSC (OR, 4.78; 95% CI, 3.17-7.22;</s><s>reference, intensive chemotherapy), whereas younger age (&lt; 60 years) was inversely associated with intensive chemotherapy.</s><s>Other predictors for non-intensive treatment or BSC were ELN adverse-risk disease, comorbidity with an HCT-CI index ≥ 3, and impaired performance status (ECOG 2-4).</s><s>With increasing comorbidity index, the association with nonintensive treatment (HCT-CI 1-2 vs. 0: OR, 1.30; 95% CI, 0.96-1.77;</s><s>HCT-CI ≥ 3 vs.</s><s>0: OR, 1.65; 95% CI, 1.20-2.65)</s><s>and BSC (HCT-CI 1-2 vs. 0: OR, 1.66; 95% CI, 1.10-2.57;</s><s>HCT-CI ≥ 3 vs.</s><s>0: OR, 2.61; 95% CI, 1.68-4.07,</s><s>respectively) became stronger.</s><s>Of note, after adjustment for the other covariates, ELN favorable risk was only rarely associated with BSC as treatment Group performance status, FLT3 FMS-related tyrosine kinase 3, HCT hematopoietic cell transplantation, ITD internal tandem duplication, N number of patients, NPM1 nucleophosmin-1, TKD tyrosine kinase domain, WT wild type strategy (OR 0.39 95% CI, 0.21-0.71),</s><s>whereas nonintensive chemotherapy was nearly as frequently chosen as intensive chemotherapy (OR 0.95 95% CI, 0.65-1.39).</s><s>Compared to BMI 20-24 kg/m 2 , obesity was less frequently associated with non-intensive treatment (OR, 0.86; 95% CI, 0.67-1.12)</s><s>and BSC (OR, 0.57; 95% CI, 0.40-0.80).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Based on the absolute numbers of 1307 patients included in 2014, the academic population-based AMLSG BiO registry study roughly represents one third of expected cases per year with newly diagnosed AML in Germany and Austria with an assumed incidence rate of 4 of 100,000 inhabitants.</s><s>However, compared to other population-based cancer registries, the agespecific incidence rate of the AMLSG BiO registry is lower for persons of older age.</s><s>Compared to the data of other cancer registries, about 20% of men aged over 70 years and women aged over 75 years with AML were registered in the AMLSG BiO registry suggesting that older AML patients were underreported.</s><s>Possible explanations are that older patients were less frequently referred to specialized leukemia-treating hospitals and that in older AML patients genetic information was considered less relevant for the treatment decision.</s><s>However, median age of 65 years at diagnosis in our AMLSG BiO registry was consistent with data reported from the Netherlands with a comparable population <ref type="bibr" target="#b28">[17]</ref>.</s><s>Thus, data from our AMLSG BiO registry shows an excellent and good population representation up to the age of 70 years and with an age between 70 and 80 years, respectively.</s></p><p><s>In our population-based approach, the distribution of selected genetic markers such as activating FLT3 mutations and mutated NPM1 differed in a clinically relevant manner from that recently reported in a large group of patients, all of them treated in interventional clinical trials with a median age below 60 years <ref type="bibr" target="#b19">[8]</ref>; interestingly, the occurrence of NPM1 mutations was very similar whereas the number of activating FLT3 mutations was lower by a factor of 1.32.</s><s>This clearly reflects patient selection towards younger and fitter patients when treated in clinical trials.</s><s>As illustrated in Fig. <ref type="figure">3d</ref> with a nearly stable absolute prevalence of patients exhibiting activating FLT3 mutations in all age groups, the relative prevalence significantly decreased from 33, 29, 24, to In the AMLSG BiO registry, most patients with AML are older with a high proportion of patients with adverse genetics (Fig. <ref type="figure">3a</ref>), presence of comorbidities (Fig. <ref type="figure">3b</ref>), and impaired performance status (Fig. <ref type="figure">3c</ref>).</s><s>However, up to the age of 75 years, most patients receive intensive chemotherapy (Fig. <ref type="figure">4</ref>), while beyond this age more patients are treated with hypomethylating agents, low-dose cytarabine, or best supportive care.</s><s>Consistent with the literature, in our study, impaired performance status and increased comorbidity index were more frequent in older age <ref type="bibr" target="#b42">[30]</ref>.</s><s>There has been a discussion about the cofactors influencing the treatment decision such as performance status and the burden of comorbidities <ref type="bibr" target="#b14">[3]</ref> as well as the genetic profile of the disease <ref type="bibr" target="#b20">[9]</ref>.</s><s>Due to all these factors, the treatment of AML in older patients remains quite challenging <ref type="bibr" target="#b42">[30]</ref>, since intensive chemotherapy is toxic and less well tolerated by the older AML patients.</s><s>Recent developments of targeted treatment for AML patients with activating FLT3 mutation have drawn the attention to this subgroup, which comprises about one quarter of our registry patients.</s><s>Although the relative number of activating FLT3 mutation decreases with increasing age, still a substantial proportion of patients above the age of 60 years may benefit from specific FLT3 inhibitors <ref type="bibr">[31]</ref>.</s><s>Thus, the differences of the genetic and clinical profiles between older and younger AML patients have to be taken into account when treatment strategies are developed <ref type="bibr">[32]</ref>.</s><s>A substantial proportion of older AML patients exhibit a NPM1 mutation, which predicts for high response rates to intensive induction therapy even in the older patients with complete remission (CR) rates as high as 80% <ref type="bibr">[33,</ref><ref type="bibr">34]</ref>.</s><s>This genetic marker information may therefore be used to guide treatment strategy in older patients.</s></p><p><s>After adjusting for disease and performance (ECOG, HCT-CI) parameters, we found overweight to be associated with the intensive treatment approach rather than non-intensive treatment and BSC.</s><s>This suggests that obese patients are considered to tolerate intensive chemotherapy better compared to normal or underweight patients.</s><s>This observation is paralleled by the finding that obese older AML patients have a better survival <ref type="bibr">[35]</ref>.</s><s>Whether the higher treatment intensity or other factors are responsible for superior survival of obese older patients remains elusive.</s></p><p><s>In conclusion, our study characterizes the academic population-based AMLSG BiO registry, which has excellent and good population coverage up to the age of 70 years and between 70 and 80 years, respectively.</s><s>Our study indicates that the distribution of the genetic profile differs in a clinically fashion relevant by age.</s><s>Taking into account relative and absolute numbers by age group, our study provides valid data for public health evaluations and the planning of interventional studies in genetically defined subgroups.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Incidence of AML 2012-2014 in the German AMLSG BiO registry (N = 3251) compared to selected German cancer registries and the US SEER program.</s><s>AML in the cancer registries Bavaria, Saarland, and North Rhine-Westphalia (NRW) and US Surveillance, Epidemiology, and End Results (SEER) 2009-2013</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 Fig. 4</head><label>24</label><figDesc><div><p><s>Fig. 2 Distribution of AML subtypes (N, %) according to the WHO 2008 classification in 2740 patients.</s><s>Abbreviations: CEBPA CCAAT/enhancer-binding protein alpha, N number of patients, NPM1 nucleophosmin-1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="7,178.02,488.75,366.41,221.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="7,51.02,53.86,493.59,373.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Study population AMLSG BiO registry 2012-2014 AML acute myeloid leukemia, AZA 5-azacytidine, BMI body mass index, BSC best supportive care, CEBPA CCAAT/enhancer-binding protein alpha, DAC decitabine, ECOG Eastern Cooperative Oncology Group performance status, ELN European LeukemiaNet, FLT3 FMS-related tyrosine kinase 3, Chi 2 test for categorical and Wilcoxon test for continuous variables comorbidity index, ECOG performance status, and activating FLT3 mutations are shown in Fig.3 a-d.</s><s>The figures show absolute numbers on the Y-axis and percentages in relation to the total number per age group in the bars.</s><s>Overall, most patients were in the age group ≥ 70 years.</s><s>The distribution of ELN risk groups changed significantly (p value &lt; 0.001) with increasing age.</s><s>In younger patients, the favorable risk group was either the most frequent (age &lt; 45 years) or the second most frequent group (age 45-59 years), whereas in older patients (age 60-69 years, age &gt; 70 years) the favorable risk group was the smallest subgroup.</s><s>However, the absolute number of patients in the favorable risk group ranged between 65 and 192 patients and was comparable in all age groups (Fig.</s></p></div></figDesc><table><row><cell>Total</cell><cell>Men</cell><cell>Women</cell><cell></cell></row><row><cell>N=3,521</cell><cell>N=1,939</cell><cell>N=1,582</cell><cell></cell></row><row><cell>Median (Q1;Q3)</cell><cell>Median (Q1;Q3)</cell><cell>Median (Q1;Q3)</cell><cell>p-value*</cell></row></table><note><p><s>HCT hematopoietic cell transplantation, ITD internal tandem duplication, LD AraC low-dose arabinoside cytosine, MDS myelodysplastic syndrome, N, number of patients, NPM1 nucleophosmin-1, Q quartile, TKD tyrosine kinase domain a</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>[29]body mass index, BSC best supportive care, CI confidence interval, ECOG Eastern Cooperative Oncology Group performance status, ELN European LeukemiaNet, HCT hematopoietic cell transplantation, N number of patients a Including azacitidine, decitabine, and low-dose cytarabine 19% in the age groups &lt; 45, 45-59, 60-69, and ≥ 70 years.This observation is consistent with findings showing that the frequency of FLT3-ITD and FLT3-TKD in adults decreases with increasing age[29].</s><s>However, with regard to the public health perspective and the planning of future clinical trials with FLT3 inhibitors, our results provide a good data basis in terms of expected absolute and relative numbers in the different age groups showing that the absolute number of older patients with activating FLT3 mutations (≥ 60 years) still exceeds that observed in younger patients (&lt; 60 years).</s></p></div></figDesc><table><row><cell>Multinomial logistic</cell><cell></cell><cell></cell><cell></cell></row><row><cell>regression for therapy, sex, age</cell><cell>Covariate</cell><cell></cell><cell>Intensive therapy (reference)</cell></row><row><cell>classes, 2010 ELN classification,</cell><cell></cell><cell></cell><cell>(N = 1654)</cell></row><row><cell>ECOG performance status, HCT</cell><cell></cell><cell></cell><cell></cell></row><row><cell>comorbidity index, and BMI</cell><cell></cell><cell></cell><cell>Non-intensive a (N = 460)</cell><cell>BSC (N = 207)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Odds ratio (95% CI)</cell><cell>Odds ratio (95% CI)</cell></row><row><cell></cell><cell>Age class (years)</cell><cell>&lt; 60</cell><cell>0.51 (0.31, 0.84)</cell><cell>0.76 (0.43, 1.34)</cell></row><row><cell></cell><cell></cell><cell>60-69</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell></cell><cell>≥ 70</cell><cell>9.91 (7.08, 13.86)</cell><cell>4.78 (3.17, 7.22)</cell></row><row><cell></cell><cell>Sex</cell><cell>Woman</cell><cell>0.97 (0.76, 1.24)</cell><cell>0.89 (0.64, 1.23)</cell></row><row><cell></cell><cell></cell><cell>Men</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell>ELN 2010 classification</cell><cell>Favorable</cell><cell>0.95 (0.65, 1.39)</cell><cell>0.39 (0.21, 0.71)</cell></row><row><cell></cell><cell></cell><cell>Intermediate-1</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell></cell><cell>Intermediate-2</cell><cell>1.10 (0.81, 1.51)</cell><cell>1.13 (0.76, 1.67)</cell></row><row><cell></cell><cell></cell><cell>Adverse</cell><cell>1.60 (1.16, 2.23)</cell><cell>1.17 (0.76, 1.79)</cell></row><row><cell></cell><cell>HCT comorbidity index</cell><cell>0</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell></cell><cell>1-2</cell><cell>1.30 (0.96, 1.77)</cell><cell>1.66 (1.10, 2.57)</cell></row><row><cell></cell><cell></cell><cell>≥ 3</cell><cell>1.65 (1.20, 2.26)</cell><cell>2.61 (1.68, 4.07)</cell></row><row><cell></cell><cell>ECOG</cell><cell>0-1</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell></cell><cell>2-4</cell><cell>1.94 (1.42, 2.65)</cell><cell>4.31 (3.01, 6.16)</cell></row><row><cell></cell><cell>BMI (kg/m 2 )</cell><cell>&lt;20</cell><cell>1.58 (0.91, 2.76)</cell><cell>1.46 (0.77, 2.78)</cell></row><row><cell></cell><cell></cell><cell>20-24</cell><cell>1</cell><cell>1</cell></row><row><cell></cell><cell></cell><cell>≥ 25</cell><cell>0.86 (0.67, 1.12)</cell><cell>0.57 (0.40, 0.80)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>31.SchlenkRF, Fiedler W, Salih HR et al (2016) Impact of age and midostaurin-dose on response and outcome in acute myeloid leukemia with FLT3-ITD: interim-analyses of the AMLSG 16-10 Trial.</s><s>Blood 128:449 32.</s><s>Tsai C-H, Hou H-A, Tang J-L et al (2016) Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</s><s>Leukemia 30:1485-1492.</s><s>https://doi.org/10.1038/leu.2016.65 33.</s><s>Schlenk RF, Döhner K, Kneba M et al (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia.</s><s>Results from the AMLSG Trial AML HD98B.</s><s>Haematologica 94:54-60.</s><s>https://doi.org/10.3324/</s><s>haematol.13378</s><s>34.</s><s>Becker H, Marcucci G, Maharry K et al (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study.</s><s>J Clin Oncol 28:596-604.</s><s>https://doi.org/10.1200/JCO.2009.</s><s>25.1496 35.</s><s>Brunner AM, Sadrzadeh H, Feng Y et al (2013) Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.</s><s>Am J Hematol 88:642-646.</s><s>https://doi.org/10.1002/ajh.23462</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Ann Hematol (2017)96:1993-2003   </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements We thank the cancer registries in Bavaria, North Rhine-Westphalia, and Saarland for the selection of the state-specific AML cases.</s></p><p><s>Austria: David Nachbaur M.D., Günter Gastl M.D., Universitätsklinikum</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with ethical standards</head><p><s>The study was approved by the ethical review boards of all participating centers.</s></p><p><s>Conflict of interest The authors declare that they have no conflict of interest.</s></p><p><s>Open Access This article is distributed under the terms of the Creative Comm ons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/),</s><s>which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Andreas</forename><surname>Petzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Krankenhaus Der Barmherzigen Schwestern Linz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Linz; Elisabeth</forename><surname>Koller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hanuschkrankenhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wien</forename><surname>Germany: Günter Schlimok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Klinikum Augsburg ; Jürgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Krauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jens</forename><surname>Kersten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Städtisches</forename><surname>Klinikum</surname></persName>
		</author>
		<editor>Jörg Westermann M.D., Charité Campus Virchow-Klinikum, Berlin</editor>
		<editor>Peter Brossart M.D., Marie von Lilienfeld-Toal M.D.</editor>
		<imprint>
			<pubPlace>Augsburg; Universitätsklinikum Bonn, Bonn; Braunschweig</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Rainer</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><surname>Kündgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Universitätsklinikum Düsseldorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Düsseldorf; Peter</forename><surname>Reimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Mohammed</forename><surname>Wattad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Kliniken Essen Süd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ev. Krankenhaus Essen-Werden gGmbH</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Michael</forename><surname>Lübbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Universitätsklinikum</forename><surname>Freiburg</surname></persName>
		</author>
		<imprint>
			<pubPlace>Freiburg</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Alexander</forename><surname>Burchardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Matthias</forename><surname>Rummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Universitätsklinikum Gießen</surname></persName>
		</author>
		<imprint>
			<pubPlace>Gießen</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Gerald</forename><surname>Wulf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lorenz Trümper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<imprint>
			<pubPlace>Universitätsklinikum Göttingen, Göttingen</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Hans</forename><surname>Salwender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<imprint>
			<pubPlace>Asklepios Klinik Altona, Hamburg</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Universitätsklinikum des Saarlandes</title>
		<author>
			<persName><forename type="first">Arnold</forename><surname>Ganser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><surname>Heuser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Brigitte Schlegelberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Medizinische Hochschule Hannover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hannover; Michael</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Gerhard</forename><surname>Held</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Städtisches Klinikum Karlsruhe gGmbH</title>
		<editor>Mark Ringhoffer M.D., Martin Bentz M.D.</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Heinz</forename><forename type="middle">A</forename><surname>Horst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Michael Kneba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Caritas-Krankenhaus Lebach</title>
		<imprint>
			<publisher>Stephan Kremers M.D</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Gerhard</forename><surname>Heil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Klinikum</forename><surname>Lüdenscheid</surname></persName>
		</author>
		<editor>Thomas Fischer M.D. / Thomas Heinicke M.D</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Universitätsklinikum</forename><surname>Magdeburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Ö R</forename><surname>Magdeburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Germany; Thomas</forename><surname>Kindler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Matthias</forename><surname>Theobald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<imprint>
			<pubPlace>Universitätsklinikum Mainz, Mainz</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Klinikum rechts der Isar der Technischen Universität München</title>
		<author>
			<persName><forename type="first">Katharina</forename><surname>Götze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Christian</forename><surname>Peschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>München; Sabine Struve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Clemens</forename><surname>Wendtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Klinikum</forename><surname>Schwabing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>München</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Claus-Henning Köhne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Klinikum</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Hans-Günther Mergenthaler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Klinikum</forename><surname>Stuttgart</surname></persName>
		</author>
		<editor>Axel Matzdorff M.D., Caritas-Klinik St</editor>
		<imprint>
			<pubPlace>Oldenburg; Theresia, Saarbrücken; Stuttgart</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Heinz Kirchen</surname></persName>
		</author>
		<author>
			<persName><surname>Krankenhaus Der Barmherzigen</surname></persName>
		</author>
		<author>
			<persName><surname>Brüder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Trier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Helmut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Salih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lothar</forename><surname>Kanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Universitätsklinikum Tübingen</surname></persName>
		</author>
		<author>
			<persName><surname>Tübingen; Hartmut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Konstanze</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Richard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Universitätsklinikum</forename><surname>Ulm</surname></persName>
		</author>
		<editor>Aruna Raghavachar M.D., Helios-Klinikum Wuppertal</editor>
		<imprint>
			<pubPlace>Ulm; Wuppertal</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Manuscript writing: GN, HD, and RFS. Final approval of manuscript: all authors. References 1. SEER Cancer Statistics Review, 1975-2009 -Previous version-SEER Cancer Statistics Review</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Gn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Se</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rfs</forename><surname>Data</surname></persName>
		</author>
		<author>
			<persName><surname>Gn</surname></persName>
		</author>
		<author>
			<persName><surname>Ef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Se</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rfs</forename></persName>
		</author>
		<ptr target="https://seer.cancer.gov/archive/csr/1975_2009_pops09/.Accessed5" />
		<imprint>
			<date type="published" when="2016-12">Dec 2016</date>
		</imprint>
	</monogr>
	<note>Author&apos;s contribution Conception and design: GN and RFS. Provision of study materials or patients: all authors. Collection and assembly of data</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<ptr target="https://seer.cancer.gov/csr/1975_2013/" />
	</analytic>
	<monogr>
		<title level="m">SEER Statistics</title>
				<imprint>
			<date type="published" when="2016-12-05">Accessed 5 Dec 2016</date>
			<biblScope unit="page" from="1975" to="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Acute myeloid leukemia and myelodysplastic syndromes in older adults</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Klepin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Pardee</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2014.55.1564</idno>
		<ptr target="https://doi.org/10.1200/JCO.2014.55.1564" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2541" to="2552" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Acute myeloid leukemia in the real world: why population-based registries are needed</title>
		<author>
			<persName><forename type="first">G</forename><surname>Juliusson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lazarevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A-S</forename><surname>Hörstedt</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2011-12-379008</idno>
		<ptr target="https://doi.org/10.1182/blood-2011-12-379008" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="3890" to="3899" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Trends in hematological cancer in the elderly in Denmark</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Ocias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vestergaard</surname></persName>
		</author>
		<idno type="DOI">10.3109/0284186X.2015.1115124</idno>
		<ptr target="https://doi.org/10.3109/0284186X.2015.1115124" />
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="98" to="107" />
			<date type="published" when="1980">2016. 1980-2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Genomics of acute myeloid leukemia diagnosis and pathways</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>in press</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Nagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Stocks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Späth</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00277-012-1489-z</idno>
		<ptr target="https://doi.org/10.1007/s00277-012-1489-z" />
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="1519" to="1531" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Genomic classification and prognosis in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Papaemmanuil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1516192</idno>
		<ptr target="https://doi.org/10.1056/NEJMoa1516192" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="2209" to="2221" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
		<idno type="DOI">10.1182/asheducation-2013.1.324</idno>
		<ptr target="https://doi.org/10.1182/asheducation-2013.1.324" />
	</analytic>
	<monogr>
		<title level="j">Hematology Am Soc Hematol Educ Program</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="324" to="330" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Weisdorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bloomfield</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMra1406184</idno>
		<ptr target="https://doi.org/10.1056/NEJMra1406184" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1136" to="1152" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</title>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amadori</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2009-07-235358</idno>
		<ptr target="https://doi.org/10.1182/blood-2009-07-235358" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="453" to="474" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa074306</idno>
		<ptr target="https://doi.org/10.1056/NEJMoa074306" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1909" to="1918" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel</title>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2016-08-733196</idno>
		<ptr target="https://doi.org/10.1182/blood-2016-08-733196" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="424" to="447" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) Pcontrolled double</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mandrekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Sanford</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">6</biblScope>
		</imprint>
	</monogr>
	<note>blind trial (CALGB 10603/RATIFY [Alliance]). Blood</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Precision oncology for acute myeloid leukemia using a knowledge bank approach</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Papaemmanuil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martincorena</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng.3756</idno>
		<ptr target="https://doi.org/10.1038/ng.3756" />
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Data quality in the Danish National Acute Leukemia Registry: a hematological data resource</title>
		<author>
			<persName><forename type="first">Lsg</forename><surname>Ostgård</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Nørgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Severinsen</surname></persName>
		</author>
		<idno type="DOI">10.2147/CLEP.S48411</idno>
		<ptr target="https://doi.org/10.2147/CLEP.S48411" />
	</analytic>
	<monogr>
		<title level="j">Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="335" to="344" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Dinmohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Van Norden</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2015.188</idno>
		<ptr target="https://doi.org/10.1038/leu.2015.188" />
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="24" to="31" />
			<date type="published" when="1989">2016. 1989-2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Minicozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mounier</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(14)70282-7</idno>
		<ptr target="https://doi.org/10.1016/S1470-2045" />
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="70282" to="70287" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Changes in the survival of older patients with hematologic malignancies in the early 21st century</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pulte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Brenner</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.30003</idno>
		<ptr target="https://doi.org/10.1002/cncr.30003" />
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="2031" to="2040" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Therapeutic advances in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wetzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Löwenberg</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2010.30.1820</idno>
		<ptr target="https://doi.org/10.1200/JCO.2010.30.1820" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="487" to="494" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Toxicity and response criteria of the Eastern Cooperative Oncology Group</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Oken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Creech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Tormey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="649" to="655" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Sorror</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Maris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Storb</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2005-05-2004</idno>
		<ptr target="https://doi.org/10.1182/blood-2005-05-2004" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="2912" to="2919" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Vardiman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Arber</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2009-03-209262</idno>
		<ptr target="https://doi.org/10.1182/blood-2009-03-209262" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="937" to="951" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">An international system for human cytogenetic nomenclature</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mitelman</surname></persName>
		</author>
		<author>
			<persName><surname>Iscn</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1995">1995. 1995. 1995</date>
			<pubPlace>Karger, Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Taskesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Van Norden</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2013-05-503847</idno>
		<ptr target="https://doi.org/10.1182/blood-2013-05-503847" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1576" to="1582" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity</title>
		<author>
			<persName><forename type="first">E</forename><surname>Taskesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corbacioglu</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2010-09-307280</idno>
		<ptr target="https://doi.org/10.1182/blood-2010-09-307280" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="2469" to="2475" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Statistisches</forename><surname>Bundesamt</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="page" from="2012" to="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Destatis</forename><surname>Statistisches Bundesamt</surname></persName>
		</author>
		<ptr target="https://www-genesis.destatis.de/genesis/online/link/tabellen/12411*" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Epidemiology</forename><surname>Surveillance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">End</forename><surname>Results</surname></persName>
		</author>
		<idno>AML incidence 2009-2013</idno>
		<ptr target="http://seer.cancer.gov/faststats/selections.php?#Output" />
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
		<respStmt>
			<orgName>National cancer Institute</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hoster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schneider</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00277-011-1280-6</idno>
		<ptr target="https://doi.org/10.1007/s00277-011-1280-6" />
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="9" to="18" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Emerging strategies for the treatment of older patients with acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Iacoboni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Montesinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Venditti</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00277-016-2666-2</idno>
		<ptr target="https://doi.org/10.1007/s00277-016-2666-2" />
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1583" to="1593" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
